Literature DB >> 20828647

Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.

Sotirios Tsimikas1, Ziad Mallat, Philippa J Talmud, John J P Kastelein, Nicholas J Wareham, Manjinder S Sandhu, Elizabeth R Miller, Joelle Benessiano, Alain Tedgui, Joseph L Witztum, Kay-Tee Khaw, S Matthijs Boekholdt.   

Abstract

OBJECTIVES: This study sought to assess whether oxidation-specific biomarkers are associated with an increased risk of coronary artery disease (CAD) events.
BACKGROUND: The relationship of a panel of oxidative biomarkers and lipoprotein(a) [Lp(a)] to CAD risk is not fully determined.
METHODS: A prospective case-control study nested in the EPIC (European Prospective Investigation of Cancer)-Norfolk cohort of 45- to 79-year-old apparently healthy men and women followed for approximately 6 years was designed. Cases consisted of participants in whom fatal or nonfatal CAD developed, matched by sex, age, and enrollment time with controls without CAD. Baseline levels of oxidized phospholipids on apolipoprotein B-100 particles and Lp(a) were measured in 763 cases and 1,397 controls. Their relationship to secretory phospholipase A(2) type IIA mass and activity, myeloperoxidase mass, and lipoprotein-associated phospholipase A(2) activity and association with CAD events were determined.
RESULTS: After adjusting for age, smoking, diabetes, low- and high-density lipoprotein cholesterol, and systolic blood pressure, the highest tertiles of oxidized phospholipids on apolipoprotein B-100 particles and Lp(a) were associated with a significantly higher risk of CAD events (odds ratios: 1.67 and 1.64, respectively; p < 0.001) compared with the lowest tertiles. The odds ratio of CAD events associated with the highest tertiles of oxidized phospholipids on apolipoprotein B-100 particles or Lp(a) was significantly potentiated (approximately doubled) by the highest tertiles of secretory phospholipase A(2) activity and mass but less so for myeloperoxidase and lipoprotein-associated phospholipase A(2) activity. The odds ratios for fatal CAD were higher than for the combined end point. After taking into account the Framingham Risk Score, c-index values progressively increased when oxidative biomarkers were added to the model.
CONCLUSIONS: This EPIC-Norfolk study links pathophysiologically related oxidation-specific biomarkers and Lp(a) with CAD events. Oxidation-specific biomarkers provide cumulative predictive value when added to traditional cardiovascular risk factors.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20828647     DOI: 10.1016/j.jacc.2010.04.048

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  49 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

Review 2.  Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.

Authors:  Shann S Yu; Ryan A Ortega; Brendan W Reagan; John A McPherson; Hak-Joon Sung; Todd D Giorgio
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-10

Review 3.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

Review 4.  Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.

Authors:  Yury I Miller; Sotirios Tsimikas
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

5.  Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.

Authors:  Young Sup Byun; Jun-Hee Lee; Benoit J Arsenault; Xiaohong Yang; Weihang Bao; David DeMicco; Rachel Laskey; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2015-04-07       Impact factor: 24.094

Review 6.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 7.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

8.  HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).

Authors:  Calvin Yeang; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-05-26       Impact factor: 5.922

Review 9.  Lipoprotein(a): A Lipoprotein Whose Time Has Come.

Authors:  Erik Kelly; Linda Hemphill
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

10.  Clinical and imaging parameters to predict cardiovascular outcome in asymptomatic subjects.

Authors:  Hyo Eun Park; Eun-Ju Chun; Sang-Il Choi; Seung-Pyo Lee; Chang-Hwan Yoon; Hyung-Kwan Kim; Tae-Jin Youn; Yong-Jin Kim; Dong-Ju Choi; Dae-Won Sohn; Goo-Yeong Cho
Journal:  Int J Cardiovasc Imaging       Date:  2013-05-08       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.